{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:49:51Z","timestamp":1792547391939,"version":"4.5.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>To determine the plasma metformin concentration threshold associated with lactic acidosis and analyze the outcome in metformin-treated patients with lactic acidosis hospitalized in an emergency context.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>A retrospective, observational, single-center study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Setting:<\/jats:title>\n            <jats:p>Emergency department and ICUs at Amiens University Hospital (Amiens, France).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients:<\/jats:title>\n            <jats:p>All consecutive patients with data on arterial lactate and pH up to 12 hours before or after a plasma metformin assay within 24 hours of admission, over a 9.7-year period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Intervention:<\/jats:title>\n            <jats:p>None.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Measurements and Main Results:<\/jats:title>\n            <jats:p>The study population consisted of 194 metformin-treated diabetic patients (median age: 68.6; males: 113 [58.2%]); 163 (84%) had acute kidney injury, which was associated variously with dehydration (45.4%), sepsis (41.1%), cardiogenic shock (20.9%), and diabetic ketoacidosis (16%). Eighty-seven patients (44.8%) had lactic acidosis defined as an arterial blood pH less than 7.35 and a lactate concentration greater than or equal to 4\u2009mM, and 38 of them (43.7%) died in the ICU. A receiver operating characteristic curve analysis showed that a metformin concentration threshold of 9.9\u2009mg\/L was significantly associated with the occurrence of lactic acidosis (specificity: 92.9%; sensitivity: 67.1%; area under the receiver operating characteristic curve: 0.83; <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.0001). Among lactic acidosis-positive patients, however, in-ICU death was less frequent when the metformin concentration was greater than or equal to 9.9\u2009mg\/L (33.9% vs 61.3% for &lt; 9.9\u2009mg\/L; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.0252). After adjustment for the Simplified Acute Physiology Score II, in-ICU death was positively associated with prothrombin activity less than 70% and negatively associated with the initiation of renal replacement therapy at admission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In metformin-treated patients admitted in an emergency context, a plasma metformin concentration greater than or equal to 9.9\u2009mg\/L was strongly associated with the presence of lactic acidosis. This threshold may assist with the delicate decision of whether or not to initiate renal replacement therapy. Indeed, the outcome of lactic acidosis might depend on the prompt initiation of renal replacement therapy\u2014especially when liver failure reduces lactate elimination.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ccm.0000000000004589","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:21:14Z","timestamp":1601511674000},"page":"e1194-e1202","source":"Crossref","is-referenced-by-count":53,"title":["A Study of Associations Between Plasma Metformin Concentration, Lactic Acidosis, and Mortality in an Emergency Hospitalization Context"],"prefix":"10.1097","volume":"48","author":[{"given":"Youssef","family":"Bennis","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France."},{"name":"MP3CV Laboratory, EA7517, University of Picardie Jules Verne, Amiens, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Bodeau","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France."},{"name":"MP3CV Laboratory, EA7517, University of Picardie Jules Verne, Amiens, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Batteux","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gras-Champel","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Masmoudi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Maizel","sequence":"additional","affiliation":[{"name":"MP3CV Laboratory, EA7517, University of Picardie Jules Verne, Amiens, France."},{"name":"Department of Intensive Care Medicine, Amiens University Hospital, Amiens, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc E.","family":"De Broe","sequence":"additional","affiliation":[{"name":"Laboratory of Pathophysiology, University of Antwerp, Antwerp, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Daniel","family":"Lalau","sequence":"additional","affiliation":[{"name":"Department of Endocrinology-Diabetology-Nutrition, Amiens University Hospital, Amiens, France."},{"name":"P\u00e9riTox UMR_I 01, University of Picardie Jules Verne, Amiens, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Lemaire-Hurtel","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"R1-20230812","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ki.2014.19","article-title":"Metformin and other antidiabetic agents in renal failure patients.","volume":"87","author":"Lalau","year":"2015","journal-title":"Kidney Int"},{"key":"R2-20230812","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1111\/dom.12974","article-title":"Metformin-associated lactic acidosis (MALA): Moving towards a new paradigm.","volume":"19","author":"Lalau","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R3-20230812","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/dme.12017","article-title":"The criteria for metformin-associated lactic acidosis: The quality of reporting in a large pharmacovigilance database.","volume":"30","author":"Kajbaf","year":"2013","journal-title":"Diabet Med"},{"key":"R5-20230812","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40262-015-0323-x","article-title":"Therapeutic concentrations of metformin: A systematic review.","volume":"55","author":"Kajbaf","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"R6-20230812","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2337\/dc17-2231","article-title":"Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4.","volume":"41","author":"Lalau","year":"2018","journal-title":"Diabetes Care"},{"key":"R7-20230812","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin.","volume":"50","author":"Graham","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"R8-20230812","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/FPC.0b013e32834c0010","article-title":"The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c.","volume":"21","author":"Christensen","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"R9-20230812","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1476-5381.2012.01853.x","article-title":"Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis.","volume":"166","author":"Toyama","year":"2012","journal-title":"Br J Pharmacol"},{"key":"R10-20230812","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1124\/jpet.109.163642","article-title":"Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine.","volume":"333","author":"Ito","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"R11-20230812","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1124\/mol.63.4.844","article-title":"Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin.","volume":"63","author":"Wang","year":"2003","journal-title":"Mol Pharmacol"},{"key":"R12-20230812","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.taap.2009.11.026","article-title":"Toxicity and toxicokinetics of metformin in rats.","volume":"243","author":"Quaile","year":"2010","journal-title":"Toxicol Appl Pharmacol"},{"key":"R13-20230812","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.yrtph.2010.05.005","article-title":"Comparison of potential risks of lactic acidosis induction by biguanides in rats.","volume":"58","author":"Bando","year":"2010","journal-title":"Regul Toxicol Pharmacol"},{"key":"R14-20230812","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/15563650.2013.860985","article-title":"Metformin accumulation: Lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy.","volume":"52","author":"Vecchio","year":"2014","journal-title":"Clin Toxicol (Phila)"},{"key":"R15-20230812","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/CCM.0b013e3181a02490","article-title":"Metformin-associated lactic acidosis: A prognostic and therapeutic study.","volume":"37","author":"Seidowsky","year":"2009","journal-title":"Crit Care Med"},{"key":"R16-20230812","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/dom.12978","article-title":"Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study.","volume":"19","author":"Connelly","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R17-20230812","doi-asserted-by":"crossref","first-page":"3545914","DOI":"10.1155\/2016\/3545914","article-title":"Lactic acidosis in diabetic population: Is metformin implicated? Results of a matched case-control study performed on the type 2 diabetes population of Grenoble Hospital University.","volume":"2016","author":"Lepelley","year":"2016","journal-title":"J Diabetes Res"},{"key":"R18-20230812","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/00002018-199920040-00006","article-title":"Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations.","volume":"20","author":"Lalau","year":"1999","journal-title":"Drug Saf"},{"key":"R19-20230812","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/dme.12959","article-title":"Unexpectedly long half-life of metformin elimination in cases of metformin accumulation.","volume":"33","author":"Kajbaf","year":"2016","journal-title":"Diabet Med"},{"key":"R20-20230812","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1464-5491.2006.01813.x","article-title":"Severe acidosis in patients taking metformin\u2013rapid reversal and survival despite high APACHE score.","volume":"23","author":"Nyirenda","year":"2006","journal-title":"Diabet Med"},{"key":"R21-20230812","doi-asserted-by":"crossref","first-page":"R149","DOI":"10.1186\/cc7137","article-title":"Metformin-associated lactic acidosis in an intensive care unit.","volume":"12","author":"Peters","year":"2008","journal-title":"Crit Care"},{"key":"R22-20230812","doi-asserted-by":"crossref","first-page":"R226","DOI":"10.1186\/cc9376","article-title":"Outcome of severe lactic acidosis associated with metformin accumulation.","volume":"14","author":"Friesecke","year":"2010","journal-title":"Crit Care"},{"key":"R23-20230812","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13054-019-2346-4","article-title":"Association of preadmission metformin use and mortality in patients with sepsis and diabetes mellitus: A systematic review and meta-analysis of cohort studies.","volume":"23","author":"Liang","year":"2019","journal-title":"Crit Care"},{"key":"R24-20230812","doi-asserted-by":"crossref","first-page":"172489","DOI":"10.1016\/j.ejphar.2019.172489","article-title":"Effects of metformin on the heart with ischaemia-reperfusion injury: Evidence of its benefits from in vitro, in vivo and clinical reports.","volume":"858","author":"Higgins","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"R25-20230812","doi-asserted-by":"crossref","first-page":"104261","DOI":"10.1016\/j.phrs.2019.104261","article-title":"The beneficial roles of metformin on the brain with cerebral ischaemia\/reperfusion injury.","volume":"146","author":"Leech","year":"2019","journal-title":"Pharmacol Res"},{"key":"R26-20230812","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.2174\/0929867324666170404143102","article-title":"Update on the protective renal effects of metformin in diabetic nephropathy.","volume":"24","author":"Eisenreich","year":"2017","journal-title":"Curr Med Chem"},{"key":"R27-20230812","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000481951","article-title":"Renoprotective effects of metformin.","volume":"138","author":"De Broe","year":"2018","journal-title":"Nephron"}],"container-title":["Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000004589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T09:20:07Z","timestamp":1691832007000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000004589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ccm.0000000000004589","relation":{},"ISSN":["0090-3493"],"issn-type":[{"value":"0090-3493","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,30]]}}}